---
pmid: '17350623'
title: PKCzetaII is a target for degradation through the tumour suppressor protein
  pVHL.
authors:
- Iturrioz X
- Parker PJ
journal: FEBS Lett
year: '2007'
full_text_available: false
doi: 10.1016/j.febslet.2007.02.059
---

# PKCzetaII is a target for degradation through the tumour suppressor protein pVHL.
**Authors:** Iturrioz X, Parker PJ
**Journal:** FEBS Lett (2007)
**DOI:** [10.1016/j.febslet.2007.02.059](https://doi.org/10.1016/j.febslet.2007.02.059)

## Abstract

1. FEBS Lett. 2007 Apr 3;581(7):1397-402. doi: 10.1016/j.febslet.2007.02.059.
Epub  2007 Mar 5.

PKCzetaII is a target for degradation through the tumour suppressor protein 
pVHL.

Iturrioz X(1), Parker PJ.

Author information:
(1)Protein Phosphorylation Laboratory, Cancer Research UK, London Research 
Institute, 44 Lincoln's Inn Fields Laboratories, London WC2A 3PX, UK.

PKCzetaII is a rapidly degraded variant of PKCzeta that suppresses epithelial 
cell polarisation. It is shown here that PKCzetaII is a target for the E3 ligase 
and tumour suppressor Von Hippel-Lindau protein (pVHL). Deletion studies 
demonstrate that the C-terminal region is required for the pVHL and proteasome 
dependent turnover of PKCzetaII, however it is the N-terminal PB1 domain of 
PKCzetaII that is required for pVHL complex formation. Reciprocal deletion 
studies define the pVHL effector domain as the dominant PKCzetaII binding site. 
The results indicate that pVHL recruits PKCzetaII via its PB1 domain and causes 
ubiquitination and degradation via the distal C-terminus of PKCzetaII.

DOI: 10.1016/j.febslet.2007.02.059
PMID: 17350623 [Indexed for MEDLINE]
